Neopath (NPTH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neopath (NPTH)

NPTH 0.000600

0.0%

Mar 7 3:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: David Neal who wrote (27)	7/18/1997 10:05:00 PM
From: bazan	of 178

This was an article released on June 26,1997 Blue Cross Panel Reviewing New Pap Smear Technologies By Louis Hau NEW YORK (Dow Jones)--The Blue Cross and Blue Shield Association is expected to issue an opinion soon on the clinical efficacy and cost effectiveness of three new technologies to replace or improve Pap smear testing for cervical cancer. The association had been scheduled to hold a press conference at 5:30 p.m. EDT Wednesday to discuss its findings, but Blue Cross officials said that the briefing may be postponed for reasons that they couldn't explain. The association's conclusions are being eagerly awaited by some Wall Street observers who believe that a positive review could increase the chances of wider reimbursement of Cytyc Corp.'s (CYTC) ThinPrep test. The Blue Cross and Blue Shield Association's Technology and Evaluation Center, or TEC, will assess the clinical efficacy and cost effectiveness of the ThinPrep, NeoPath Inc.'s (NPTH) AutoPap test and Neuromedical Systems Inc.'s (NSIX) PapNet system. The Food and Drug Administration has approved the ThinPrep for use as a primary screener of cervical cancer, while the AutoPap and PapNet have been approved for back-up screening of Pap smears. The association is the nationwide membership group of 58 Blue Cross and Blue Shield health plans. The TEC periodically reviews new medical products, devices and procedures. Its non-binding opinions are often used by Blue Cross plans, health-maintenance organizations and insurance companies to formulate reimbursement policies. The Blue Cross and Blue Shield Association has canceled its press conference that was to focus on the new Pap smear technologies, according to Ellen Pearson, director of marketing for the association. She said that the association has decided to table its cost-effectiveness analysis and that it will issue a final report at a later date. She declined further comment.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next